Neoadjuvant Cemiplimab Shows Potential as an Option for Cutaneous SCC

(MedPage Today) -- MADRID -- Treatment with cemiplimab (Libtayo) followed by surgery showed encouraging survival rates in patients with resectable stage II-IV cutaneous squamous cell carcinoma (SCC), according to follow-up results from a small...
Source: MedPage Today Dermatology - Category: Dermatology Source Type: news